Prolonged release oxycodone–naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extensionClaudia Trenkwalder, Ralf Kohnen, Juliane Winkelmann et al.|The Lancet Neurology|2013Cited by 227
Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O<sup>6</sup>-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS TrialUlrich Herrlinger, Martin Glas, Niklas Schäfer et al.|Journal of Clinical Oncology|2016Cited by 197
Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: Results from a multi‐center, randomized, active controlled trialClaudia Trenkwalder, Heike Beneš, Ludger Grote et al.|Movement Disorders|2007Cited by 106
Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-non-methylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial.Ulrich Herrlinger, Martin Glas, Niklaus Schaefer et al.|Journal of Clinical Oncology|2013Cited by 29